$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
What are the side effects of taking alectinib and how long can it be used?
2025-10-19 11:44:20
Check Details
What are the side effects of ceritinib, and can the side effects be reduced by adjusting the dose
2025-10-19 11:44:20
Check Details
How to deal with diarrhea after taking ceritinib, what should you pay attention to in your diet
2025-10-19 11:44:20
Check Details
What are the adverse reactions of lorlatinib and how to alleviate them
2025-10-19 11:44:20
Check Details
What are the side effects of TAK788 and are they serious
2025-10-19 11:44:20
Check Details
What are the adverse reactions and precautions of TAK788
2025-10-19 11:44:20
Check Details
What are the side effects of amg510 targeted drug
2025-10-19 11:44:20
Check Details
What are the adverse reactions of Platinib (Pujihua)
2025-10-19 11:44:20
Check Details
What are the adverse reactions and treatment methods of larotrectinib
2025-10-19 11:44:20
Check Details
What are the adverse reactions of capmatinib
2025-10-19 11:44:20
Check Details
What are the side effects of serpatinib and how long does it take to stop taking it?
2025-10-19 11:44:20
Check Details
What are the side effects of Lorlatinib
2025-10-19 11:44:20
Check Details
1
2
...
4099
4100
4101
4102
4103
4104
4105
...
4151
4152
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Trodelvy® (Sacituzumab Govitecan-hziy): A Life-Changing ADC for Advanced Cancers
2
A Revolutionary Targeted Therapy for Hematological Malignancies
3
A New Option for Advanced Renal Cell Carcinoma Treatment
4
Trametinib (Mekinist): Precision MEK1/2 Inhibition Transforming Cancer Care Short Description:
5
Pirtobrutinib: A Novel BTK Inhibitor Offering Hope for Hematologic Cancer Patients Short Description:
6
Sacituzumab Govitecan: Trop-2 Targeted ADC Clinical Medication Guide
7
Fulvestrant (Faslodex) Breast Cancer Guide: Indications, Dosage and Safety Specifications
8
Adagrasib (Krazati): Full Guide to KRAS G12C Inhibitor for Cancer Treatment
9
Comprehensive Analysis of the Third-Generation EGFR-TKI
10
ATOMIC Study: Atezolizumab Plus Chemo Improves DFS in dMMR Stage III Colon Cancer
11
Oncology Immunotherapy vs Anti-Inflammatory Biologic: Dostarlimab vs Secukinumab - A Mechanism-Centered Comparison
12
Third-Generation TKI Redefining Treatment for ALK+ & ROS1+ NSCLC